Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare functional and anatomic outcome of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA)treatments in neovascular age-related macular degeneration by using the treat and extend (TE) protocol. Methods: In this retrospective chart study, treatment naïve 74 eyes of 74 age-related macular degeneration patients treatedwith IVR and IVA (38 eyes in IVR and 36 eyes in IVA group) with TE protocol were included. Following three consecutivemonthly intravitreal injections, TE protocol was applied to each group. Patients were followed up for at least 36 months. Mean change in best-corrected visual acuity (BCVA), central macula thickness (CMT) and injection numbers over 3 years werecompared. Results: Among 36 months period, the mean number of injections was 17 ± 4 for both groups (p > 0.05). In terms of CMT,there was no statistically significant difference between groups at 36 months compared to baseline. A decrease of 72.55 ±39.37 μm in CMT was detected in IVR group, whereas the decrease was 70.58 ± 33.96 μm in IVA group (p > 0.05). There was asignificant increase in BCVA at 36 months of measurements. In addition, BCVA demonstrated an increase of 4.1 ± 0.44 lettersin IVR group and 4.36 ± 0.67 letters in IVA group after 36 months compared to the baseline (p > 0.05). Conclusions: Both IVR and IVA injections provided significant improvements and stability in BCVA and CMT, however therewas no significant difference between IVR and IVA injections with TE protocol of 36 months.
Abstract
Purpose: To compare functional and anatomic outcome of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA)treatments in neovascular age-related macular degeneration by using the treat and extend (TE) protocol. Methods: In this retrospective chart study, treatment naïve 74 eyes of 74 age-related macular degeneration patients treatedwith IVR and IVA (38 eyes in IVR and 36 eyes in IVA group) with TE protocol were included. Following three consecutivemonthly intravitreal injections, TE protocol was applied to each group. Patients were followed up for at least 36 months. Mean change in best-corrected visual acuity (BCVA), central macula thickness (CMT) and injection numbers over 3 years werecompared. Results: Among 36 months period, the mean number of injections was 17 ± 4 for both groups (p > 0.05). In terms of CMT,there was no statistically significant difference between groups at 36 months compared to baseline. A decrease of 72.55 ±39.37 μm in CMT was detected in IVR group, whereas the decrease was 70.58 ± 33.96 μm in IVA group (p > 0.05). There was asignificant increase in BCVA at 36 months of measurements. In addition, BCVA demonstrated an increase of 4.1 ± 0.44 lettersin IVR group and 4.36 ± 0.67 letters in IVA group after 36 months compared to the baseline (p > 0.05). Conclusions: Both IVR and IVA injections provided significant improvements and stability in BCVA and CMT, however therewas no significant difference between IVR and IVA injections with TE protocol of 36 months.
참고문헌 (24)
- Li JQ, "Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis", Br J Ophthalmol, 104, pp.1077~1084 (2020)
- Wong WL, "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis", Lancet Glob Health, 2, pp.e106~e116 (2014)
- Ozkaya A, "Real-world outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in Turkey: a multicenter retrospective study, Bosphorus Retina Study Group Report No: 1", Turk J Ophthalmol, 48, pp.232~237 (2018)
- Yamamoto-Rodriguez L, "New frontiers and clinical implications in the pathophysiology of age-related macular degeneration", Med Clin (Barc), 154, pp.496~504 (2020)
- Wolff B, "Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: a single-centre French study", Clin Exp Ophthalmol, 48, pp.636~643 (2020)
- Blick SK, "Ranibizumab", Drugs, 67, pp.1199~1209 (2007)
- Verner-Cole EA, "Aflibercept for the treatment of neovascular age-related macular degeneration", Drugs Today (Barc), 48, pp.317~329 (2012)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Heier JS, "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Schmidt-Erfurth U, "Intravitreal af libercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies", Ophthalmology, 121, pp.193~201 (2014)
- Distler O, "The molecular control of angiogenesis", Int Rev Immunol, 21, pp.33~49 (2002)
- Lalwani GA, "A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study", Am J Ophthalmol, 148, pp.43~58 (2009)
- Karacorlu M, "Risk-based algorithm-guided treatment protocol for the management of neovascular age-related macular degeneration", Turk J Ophthalmol, 49, pp.258~269 (2019)
- Lanzetta P, "Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases", Graefes Arch Clin Exp Ophthalmol, 255, pp.1259~1273 (2017)
- Skelly A, "Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients", Vision (Basel), 3, pp.41~ (2019)
- Schmucker CM, "Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis", PLoS One, 10, pp.e0137866~ (2015)
- Augsburger M, "Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study", Graefes Arch Clin Exp Ophthalmol, 257, pp.1889~1895 (2019)
- Spitzer MS, "Treatment of age-related macular degeneration: focus on ranibizumab", Clin Ophthalmol, 2, pp.1~14 (2008)
- Berg K, "An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration", Acta Ophthalmol, 95, pp.796~802 (2017)
- Smit C, "Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study", J Comp Eff Res, 7, pp.561~567 (2018)
- Gillies MC, "Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration:a randomized clinical trial", JAMA Ophthalmol, 137, pp.372~379 (2019)
- Garweg JG, "Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24 months", J Ocul Pharmacol Ther, 33, pp.567~572 (2017)
- Ohji M, "Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years:network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison", Adv Ther, 37, pp.2184~2198 (2020)